- Home
- RNW vs IMVT Comparison
RNW vs IMVT Comparison
Compare RNW & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNW
- IMVT
- Stock Information
- Founded
- RNW 2011
- IMVT 2018
- Country
- RNW United Kingdom
- IMVT United States
- Employees
- RNW N/A
- IMVT N/A
- Industry
- RNW Electric Utilities: Central
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNW Utilities
- IMVT Health Care
- Exchange
- RNW Nasdaq
- IMVT Nasdaq
- Market Cap
- RNW 2.4B
- IMVT 2.7B
- IPO Year
- RNW N/A
- IMVT N/A
- Fundamental
- Price
- RNW $7.46
- IMVT $18.12
- Analyst Decision
- RNW Strong Buy
- IMVT Buy
- Analyst Count
- RNW 1
- IMVT 10
- Target Price
- RNW $7.50
- IMVT $40.14
- AVG Volume (30 Days)
- RNW 1.4M
- IMVT 1.3M
- Earning Date
- RNW 08-14-2025
- IMVT 08-05-2025
- Dividend Yield
- RNW N/A
- IMVT N/A
- EPS Growth
- RNW 16.07
- IMVT N/A
- EPS
- RNW 0.13
- IMVT N/A
- Revenue
- RNW $1,135,947,896.00
- IMVT N/A
- Revenue This Year
- RNW N/A
- IMVT N/A
- Revenue Next Year
- RNW $17.72
- IMVT N/A
- P/E Ratio
- RNW $58.93
- IMVT N/A
- Revenue Growth
- RNW 19.36
- IMVT N/A
- 52 Week Low
- RNW $5.15
- IMVT $12.72
- 52 Week High
- RNW $7.67
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- RNW 63.67
- IMVT 68.50
- Support Level
- RNW $7.41
- IMVT $16.88
- Resistance Level
- RNW $6.94
- IMVT $17.10
- Average True Range (ATR)
- RNW 0.17
- IMVT 0.71
- MACD
- RNW 0.06
- IMVT 0.16
- Stochastic Oscillator
- RNW 82.08
- IMVT 99.65
About RNW ReNew Energy Global plc
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.